促进胃肠道健康:黄素的有效性和纳米制剂
Jialin Ji1, Zhaojie Ma2, Yingshuai Wang3
1School of Clinical Medicine, Shandong Second Medical University, Weifang 261053, China.
Molecules (Basel, Switzerland)
|April 13, 2024
概括
黄素 (CCM) 对胃肠道疾病具有治疗潜力,但其生物利用性不佳. 纳米制剂提供了一个有前途的策略来增强CCM.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 纳米医学是一种纳米医学.
- 胃肠病学 胃肠病学
背景情况:
- 黄 (CCM) 是一种来自黄的多,具有广泛的生物活性,包括抗炎和抗氧化特性.
- 胃肠道疾病对全球健康构成重大负担,需要有效的治疗策略.
- CCM的水溶性较差和生物利用率较低限制了其治疗效果.
研究的目的:
- 审查CCM在胃肠道疾病中的机制和治疗效果.
- 探索纳米制剂在增强CCM疗效方面的作用.
- 评估目前的临床环境和未来的方向,在胃肠病学中使用CCM.
主要方法:
- 关于黄素 (CCM) 治疗胃肠道疾病的临床前和临床研究的文献综述.
- 对研究的分析,重点是纳米制剂策略,以提高CCM生物可用性.
- 综合证据关于CCM的治疗机制和临床应用.
主要成果:
- 黄素 (CCM) 在治疗各种胃肠道疾病方面显示出潜力.
- 纳米制剂显著提高了CCM的水溶性和生物可用性,改善了体外和临床前模型中的治疗结果.
- 有许多临床试验用于CCM与其他药物结合,但很少使用CCM纳米材料.
结论:
- 纳米制备的黄素 (CCM) 有望改善胃肠道疾病的治疗.
- 需要进一步的研究来调查CCM纳米制剂中使用的载体的安全性.
- 将CCM纳米制剂的有希望的临床前发现转化为临床实践是一个关键的未来方向.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
423
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
423
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249